Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

MULTIVITAMINS

All products: not a benefit

Pregnancy Multivitamin Folic 5 · DIN 02537478 · · tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since 2026-08-03 · checked 2026-09-20 · What does dormant mean?
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Pregnancy Multivitamin Folic 5 · DIN 02537478 Manufacturer: Jamp Pharma Corporation; listing date 2025-02-28 Health Canada: Dormant since 2026-08-03 · brand PREGNANCY MULTIVITAMIN FOLIC 5 · ATC B03AE04 IRON, MULTIVITAMINS AND MINERALS · form Tablet · route Oral · ingredients BETA-CAROTENE 1.6 MG, VITAMIN B1 (THIAMINE MONONITRATE) 3 MG, VITAMIN B2 (VITAMIN B2) 3.4 MG, NICOTINAMIDE 20 MG, D-PANTOTHENIC ACID (CALCIUM D-PANTOTHENATE) 5 MG, VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE) 10 MG, ASCORBIC ACID 120 MG, VITAMIN E (DL-ALPHA TOCOPHERYL ACETATE) 13.8 MG, COPPER (COPPER GLUCONATE) 2 MG, IODINE (POTASSIUM IODIDE) 0.15 MG, IRON (FERROUS FUMARATE) 35 MG, MAGNESIUM (MAGNESIUM OXIDE) 50 MG, ZINC (ZINC OXIDE) 15 MG, FOLIC ACID 5 MG, VITAMIN B12 (VITAMIN B12) 12 MCG, VITAMIN D3 (VITAMIN D3) 600 UNIT, CALCIUM (CALCIUM CARBONATE) 300 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102618 · Verify on the e-Formulary ↗ (DIN 02537478)

Source record
DIN 02537478: Pregnancy Multivitamin Folic 5 Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 882800067; group id 889; item number 2136; lccId None; manufacturer id JPC Source form: Tab; strength: None Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.5025; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02537478 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102618
Interchangeable products
Pregvit Folic 5 · DIN 02451581 · not recorded
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Dormant since 2026-08-03 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (88:28 Multivitamins) and how they are covered

Matched class: 88:28 Multivitamins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: MULTIVITAMINS FOR INFUSION 88:28 Multivitamins

MULTIVITAMINS FOR INFUSION

· 2 products · General benefit · strengths: · Inj-2x5mL Vial Pk, Inj-4mL+1mL Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 88:28
Full class listing Related classes: 88:08 Vitamin B, 88:12 Vitamin C, 88:16 Vitamin D Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Pregnancy Multivitamin Folic 5: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026